Döhner, H. et al. Prognosis and administration of AML in adults: 2022 suggestions from a world knowledgeable panel on behalf of the ELN. Blood 22, 1345–1377 (2022).
Siegel, R. L., Miller, Ok. D., Wagle, N. S. & Jemal, A. Most cancers statistics, 2023. CA Most cancers J. Clin. 73, 17–48 (2023).
Quick, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593–606 (2018).
Jahn, E. et al. Scientific affect of the genomic panorama and leukemogenic trajectories in non-intensively handled aged acute myeloid leukemia sufferers. Leukemia 37, 2187–2196 (2023).
Most cancers Genome Atlas Analysis Community et al. Genomic and epigenomic landscapes of grownup de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: A complete evaluation and 2016 replace. Blood Most cancers J. 6, e441 (2016).
Boffo, S., Damato, A., Alfano, L. & Giordano, A. CDK9 inhibitors in acute myeloid leukemia. J. Exp. Clin. Most cancers Res. 37, 36 (2018).
Kantarjian, H. et al. Intensive chemotherapy doesn’t profit most older sufferers (age 70 years or older) with acute myeloid leukemia. Blood 116, 4422–4429 (2010).
Pettit, Ok. & Odenike, O. Defining and treating older adults with acute myeloid leukemia who’re ineligible for intensive therapies. Entrance. Oncol. 5, 280 (2015).
Dombret, H. et al. Worldwide section 3 research of azacitidine vs typical care regimens in older sufferers with newly recognized AML with >30% blasts. Blood 126, 291–299 (2015).
Hafezi, S. & Rahmani, M. Concentrating on BCL-2 in most cancers: Advances, challenges, and views. Cancers (Basel) 13, 1292 (2021).
Cong, H. et al. Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: present standing and views. J. Med. Chem. 62, 5750–5772 (2019).
Fulda, S. Therapeutic exploitation of necroptosis for most cancers remedy. Semin. Cell Dev. Biol. 35, 51–56 (2014).
Edinger, A. L. & Thompson, C. B. Dying by design: Apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16, 663–669 (2004).
Shimizu, S., Yoshida, T., Tsujioka, M. & Arakawa, S. Autophagic cell loss of life and most cancers. Int. J. Mol. Sci. 15, 3145–3153 (2014).
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. & Kroemer, G. Molecular mechanisms of necroptosis: An ordered mobile explosion. Nat. Rev. Mol. Cell Biol. 11, 700–714 (2010).
Dixon, S. J. et al. Ferroptosis: An iron-dependent type of nonapoptotic cell loss of life. Cell 149, 1060–1072 (2012).
Shi, J., Gao, W. & Shao, F. Pyroptosis: Gasdermin-mediated programmed necrotic cell loss of life. Traits Biochem. Sci. 42, 245–254 (2017).
Jin, Z. & El-Deiry, W. S. Overview of cell loss of life signaling pathways. Most cancers Biol. Ther. 4, 139–163 (2005).
van Bathroom, G. et al. The position of mitochondrial elements in apoptosis: A Russian roulette with multiple bullet. Cell Dying Differ. 9, 1031–1042 (2002).
Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell loss of life. Physiol. Rev. 87, 99–163 (2007).
Tsujimoto, Y. & Shimizu, S. Bcl-2 household: Life-or-death change. FEBS Lett. 466, 6–10 (2000).
Gandhi, L. et al. Part I research of navitoclax (ABT-263), a novel Bcl-2 household inhibitor, in sufferers with small-cell lung most cancers and different stable tumors. J. Clin. Oncol. 29, 909–916 (2011).
Rudin, C. M. et al. Part II research of single-agent navitoclax (ABT-263) and biomarker correlates in sufferers with relapsed small cell lung most cancers. Clin. Most cancers Res. 18, 3163–3169 (2012).
Wilson, W. H. et al. Navitoclax, a focused high-affinity inhibitor of BCL-2, in lymphoid malignancies: A section 1 dose-escalation research of security, pharmacokinetics, pharmacodynamics, and antitumour exercise. Lancet Oncol. 11, 1149–1159 (2010).
Roberts, A. W. et al. Substantial susceptibility of continual lymphocytic leukemia to BCL2 inhibition: Outcomes of a section I research of navitoclax in sufferers with relapsed or refractory illness. J. Clin. Oncol. 30, 488–496 (2012).
Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor exercise whereas sparing platelets. Nat. Med. 19, 202–208 (2013).
Kater, A. P. et al. Venetoclax plus rituximab in relapsed continual lymphocytic leukemia: 4-year outcomes and analysis of affect of genomic complexity and gene mutations from the MURANO section III research. J. Clin. Oncol. 38, 4042–4054 (2020).
DiNardo, C. D. et al. Azacitidine and venetoclax in beforehand untreated acute myeloid leukemia. N. Engl. J Med. 383, 617–629 (2020).
Wei, A. H. et al. Venetoclax plus LDAC for newly recognized AML ineligible for intensive chemotherapy: A section 3 randomized placebo-controlled trial. Blood 135, 2137–2145 (2020).
Oyogoa, E., Traer, E., Tyner, J. & Lachowiez, C. Constructing on foundations: Venetoclax-based combos within the therapy of acute myeloid leukemia. Cancers (Basel) 15, 3589 (2023).
Eide, C. A. et al. Scientific correlates of venetoclax-based mixture sensitivities to reinforce acute myeloid leukemia remedy. Blood Most cancers Discov. 4, 452–467 (2023).
Xie, C. et al. Bcl-2 inhibition mixed with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Dying Dis. 14, 573 (2023).
Matsuzaki, Y., Sowa, Y., Hirose, T., Yokota, T. & Sakai, T. Histone deacetylase inhibitors-promising brokers for “gene-regulating chemoprevention” and “molecular-targeting prevention” of cancer-. Environ. Well being Prev. Med. 8, 157–160 (2003).
Hitomi, T., Matsuzaki, Y., Yokota, T., Takaoka, Y. & Sakai, T. p15(INK4b) in HDAC inhibitor-induced progress arrest. FEBS Lett. 554, 347–350 (2003).
Sonnemann, J. et al. Histone deacetylase inhibitors require caspase exercise to induce apoptosis in lung and prostate carcinoma cells. Most cancers Lett. 232, 148–160 (2006).
Cho, S. D. et al. Vital position of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate most cancers cells. Eur. J. Most cancers Prev. 15, 57–63 (2006).
Kuefer, R. et al. Sodium butyrate and tributyrin induce in vivo progress inhibition and apoptosis in human prostate most cancers. Br. J. Most cancers 90, 535–541 (2004).
Fass, D. M. et al. Impact of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate growth and neuronal chromatin. ACS Med. Chem. Lett. 2, 39–42 (2010).
Verma, M. S. et al. A standard mechanism hyperlinks actions of butyrate within the colon. ACS Chem. Biol. 13, 1291–1298 (2018).
MacFarlane, M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 139, 89–97 (2003).
Ashkenazi, A. et al. Security and antitumor exercise of recombinant soluble Apo2 ligand. J. Clin. Investig. 104, 155–162 (1999).
Walczak, H. et al. Tumoricidal exercise of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157–163 (1999).
Nakata, S. et al. Histone deacetylase inhibitors upregulate loss of life receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23, 6261–6271 (2004).
Yoshida, T. et al. Tumor necrosis factor-related apoptosis-inducing ligand is a novel transcriptional goal of runt-related transcription issue 1. Int. J. Oncol. 60, 6 (2022).
Bagger, F. O., Kinalis, S. & Rapin, N. BloodSpot: A database of wholesome and malignant haematopoiesis up to date with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 47, D881–D885 (2019).
Oki, S. et al. ChIP-Atlas: A knowledge-mining suite powered by full integration of public ChIP-seq information. EMBO Rep. 19, e46255 (2018).
Melnikov, V. Y. et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J. Clin. Investig. 110, 1083–1091 (2002).
Caserta, T. M., Smith, A. N., Gultice, A. D., Reedy, M. A. & Brown, T. L. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8, 345–352 (2003).
Rohn, T. T., Kokoulina, P., Eaton, C. R. & Poon, W. W. Caspase activation in transgenic mice with Alzheimer-like pathology: Outcomes from a pilot research using the caspase inhibitor, Q-VD-OPh. Int. J. Clin. Exp. Med. 2, 300–308 (2009).
DiNardo, C. D. et al. Molecular patterns of response and therapy failure after frontline venetoclax combos in older sufferers with AML. Blood 135, 791–803 (2020).
Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based remedy in sufferers with acute myeloid leukemia. Most cancers Discov. 10, 536–551 (2020).
Hege Hurrish, Ok. et al. Co-targeting of HDAC, PI3K, and Bcl-2 leads to metabolic and transcriptional reprogramming and decreased mitochondrial perform in acute myeloid leukemia. Biochem. Pharmacol. 205, 115283 (2022).
Valdez, B. C. et al. Enhanced cytotoxicity of bisantrene when mixed with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma 63, 1634–1644 (2022).
Egorin, M. J., Yuan, Z. M., Sentz, D. L., Plaisance, Ok. & Eiseman, J. L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Most cancers Chemother. Pharmacol. 43, 445–453 (1999).
Heidor, R., Ortega, J. F., de Conti, A., Ong, T. P. & Moreno, F. S. Anticarcinogenic actions of tributyrin, a butyric acid prodrug. Curr. Drug Targets 13, 1720–1729 (2012).
Miyoshi, M. et al. Oral administration of tributyrin will increase focus of butyrate within the portal vein and prevents lipopolysaccharide-induced liver harm in rats. Clin. Nutr. 30, 252–258 (2011).
Dyer, E. S. et al. Phenylbutyrate inhibits the invasive properties of prostate and breast most cancers cell traces within the sea urchin embryo basement membrane invasion assay. Int. J. Most cancers 101, 496–499 (2002).
Svechnikova, I. et al. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int. J. Oncol. 22, 579–588 (2003).
Iannitti, T. & Palmieri, B. Scientific and experimental functions of sodium phenylbutyrate. Medicine R D. 11, 227–249 (2011).
Shimazu, T. et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211–214 (2013).
Kong, G. et al. The ketone metabolite β-hydroxybutyrate attenuates oxidative stress in spinal twine harm by suppression of sophistication I histone deacetylases. Neurotrauma 34, 2645–2655 (2017).
Chriett, S. et al. Outstanding motion of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti inflammatory molecule. Sci. Rep. 9, 742 (2019).
Xing, A. et al. As a Histone deacetylase inhibitor, γ-aminobutyric acid upregulates GluR2 expression: An in vitro and in vivo research. Mol. Nutr. Meals Res. 63, e1900001 (2019).
Kumar, S. Ok. et al. Venetoclax or placebo together with bortezomib and dexamethasone in sufferers with relapsed or refractory a number of myeloma (BELLINI): A randomised, double-blind, multicentre, section 3 trial. Lancet Oncol. 21, 1630–1642 (2020).
Lindeman, G. J. et al. VERONICA: Randomized section II research of fulvestrant and venetoclax in ER-positive metastatic breast most cancers post-CDK4/6 inhibitors—Efficacy, security, and biomarker outcomes. Clin. Most cancers Res. 28, 3256–3267 (2022).
Hoang, D. H. et al. Synergy of venetoclax and 8-chloro-adenosine in AML: The interaction of rRNA inhibition and fatty acid metabolism. Cancers (Basel) 14, 1446 (2022).
Buettner, R. et al. Concentrating on the metabolic vulnerability of acute myeloid leukemia blasts with a mix of venetoclax and 8-chloro-adenosine. J. Hematol. Oncol. 14, 70 (2021).
Stevens, B. M. et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat. Most cancers 1, 1176–1187 (2020).
